From his beginning of adolescence, Deshawn “DJ” Chow was not sure that he could never live a normal life. The overwhelming episodes of pain caused by his sickle cell anemia have gradually aggravated.
“It’s just a difficult school to jump and always be in and out of the hospital,” said the 19 -year -old. “And just intense pain in … my head and lower back.”
When new therapies on sickle cell genes have been approved by the Food and Drug Administration a little over a year ago, the adopted parents of Chow sought City of Hope Children’s Cancer in Los Angeles to give it access to new treatment. To their relief, the center accepted it as a patient and quickly obtained the authorization of the insurance sponsored by the employer of the Chows.
“They cover almost all that [at] Almost no pocket cost for us. So we are really grateful for these advantages, “said DJ’s father Sean Chow.” I am amazed. “”
DJ Chow is part of a handful of hospital patients who have been treated with CASGEVY, FAUCILLE gene therapy produced by Green Pharmaceuticalswhich costs more than $ 2 million per patient. The processing process involved several hospitalizations as well as chemotherapy treatments at an additional cost during the past year.
Drépanocytosis is a blood disorder in which the red blood cells of a person become a crescent moon. It disproportionately affects blacks and causes episodes of intense pain that can frequently land patients in the hospital.
Chow is one of the little patients to complete the treatment with new gene therapies. After finishing the full course of Casgevy treatments in January, he begins to be dreaming of doing things he always wanted to do.
“Teach Snowboard and surf and do all these things … experiences that I never really have to do because of my sickle cell anemia,” he said.
Slow slowdown
While more than 100,000 Americans suffer from sickle cell anemia, younger patients whose organs have not been damaged by the disease are the most promising candidates to benefit from new treatments.
However, the rise of the ability to treat long -scale patients has been slow. During the first year which followed two genetic therapies for sickle cell cells approved by the FDA, just over 100 patients underwent treatment.
The leaders of Vertex said that when calling the results of the fourth quarter of the company, that 50 patients worldwide received their first cell collections by the end of last year 2024. Meanwhile, competitors’ leaders BlueBird Organic said last fall that almost five dozen patients had undergone treatment with his medication in Lyfgénie, which is at the price of more than $ 3 million per patient. 37 other patients should start treatment with the treatment of BlueBird at the beginning of 2025.
For the first treatment centers to offer new therapies on sickle genes, coordination with insurers on obtaining coverage required a little learning curve.
“It is much more fluid today than when we started to bring in patients,” said Jennifer Cameron, executive director of access to patients at the National Children’s Hospital, in Washington, DC “with several Recovered, we will send them the billing and coding guides that are developed by the … manufacturer and we share this with the payer, if they do not know. “
Dr. Leo Wang of the city of Hope, the pediatric hematologist, who works with Chow, also said that the process had become more fluid, but he is worried that the price of these treatments still sets obstacles to coverage.
“The challenges of the health system are immense. This is very expensive therapy,” he said, “for insurance regimes based on the employer, it can be a little difficult to ‘Adapt to these costs. “
Until now, the slow increase in patients in treatment has rendered the coverage of the first manageable cases, said David Joyner, CEO of CVS Health, the parent company of health insurer Aetna. But with the demand that should increase, he said that many members of the industry plan to develop new payment models for sickle cell treatments and other gene therapies on the horizon.
“There are pools of emerging risks under development … Sometimes at the state Medicaid levels, and sometimes collectively between the greatest payers,” said Joyner, so that the financial burden of treatments is spreading beyond a single state or a single company.
“You must think of a different payment model, because today’s payment model is not built to distribute the cost,” he said. “But it takes time.”
A challenge for Medicaid
For Medicaid State programs, the challenge of affordability for new sickle cell treatments can be even greater. More than half of sickle cell patients are covered by the federal government’s health plan for low -income Americans.
South states such as Georgia, Florida and Mississippi have the highest concentrations of sickle cell patients, according to a study by researchers from the University of Chicago.
Biden administration has developed a cell and gene therapy payment model as part of for Medicare and Medicaid centers, which will provide a reduced price based on results and will provide certain funding for new drugs. The deadline for states to apply for the program is on February 28, with the first federal subsidies to help pay medicines on the right track to start in June, according to CMS officials.
As part of the new payment model, states may receive up to $ 9.5 million in federal funding, but even with reduced prices that may not start covering the treatment costs of Medicaid patients in some cases.
Researchers from Oregon Health & Science University have calculated that the 10 states with the largest populations of sickle cell anemia could see an average budgetary impact of $ 30 million, based on an estimate of treatments at the price of a bit Less than $ 1.9 million.
These increased costs would take place at a time when the Trump administration and the Republican controlled congress are looking for means of reducing federal spending. Administration has already started to reduce staff in health agencies, and federal funding for Medicaid state programs should be on the table in future budgetary proposals.
The Secretary of Health and Social Services, Robert F. Kennedy Jr. on the whole.
“I have a lot of friends who have sickle cell anemia. I saw the suffering they endure,” said Kennedy. “Now there are promising gene therapies. They are very, very expensive, but it’s something that [National Institutes of Health] should be supported with enthusiasm – this kind of research. “”
Sean Chow said he was grateful to researchers who have developed gene therapy, who, according to him, will allow his son to have a more normal future, without debilitating episodes of pain. He wants other families to have the same opportunity to access the high prices for their relatives for their loved ones.
“Having a child with a sickle cell anemia has been heartbreaking,” he said. “I hope that more and more patients get the therapy, the cost can be driven.”